Faes Farma, S.A.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Faes Farma, S.A.
Immunocore looked set to be another UK biotech disappointment, before it turned around its fortunes with the launch of Kimmtrak. CEO Bahija Jallal talked to Scrip about how she has steered the company to commercial success with its debut product.
Transactions involving Biocon/Zentiva, CrystalGenomics/PanGen, Umoja/IASO, Marinus/Tenacia, Ono/Captor and Daewoong/HitGen plus deals in brief.
The first-in-class ET-1 receptor antagonist has met the primary endpoint in a pivotal resistant hypertension trial, sparking filing plans that could see the drug establish a stronghold in the multi-billion dollar market.
Despite all of the buzz around adoption of digital health tools and whopping VC investments in consumer-facing digital health firms, pharma has yet to articulate a business model for co-development or integration of behavior-modifying digital therapeutics into their portfolios.
- Generic Drugs
- OTC, Consumer
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.